stella
PsoriasisSeptember 2024Summary reviewed November 2026

Psoriasis Patients Who Clear Completely Can Space Out Injections From Every 8 to Every 16 Weeks

Patients with moderate-to-severe psoriasis who achieved complete skin clearance early on maintained that clear skin just as well when their injections were spaced out to every 16 weeks instead of every 8 weeks. About 92% of both groups kept their skin clear over 40 weeks of follow-up.

What the trial was testing

The GUIDE enrolled 880 patients with psoriasis. The study was sponsored by Janssen-Cilag International NV and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

92% of super responders kept psoriasis controlled with injections every 16 weeks instead of every 8.

JAMA dermatology · 2024 · NCT03818035

These findings — that maintained clear skin with every-16-week dosing vs every-8-week dosing — were published in the JAMA dermatology and represent the headline result of the study.

Researchers tracked outcomes across 880 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with psoriasis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

If you get complete skin clearance early from this treatment, you may be able to space out your injections and still stay clear—meaning fewer doctor visits and injections. This is the first solid evidence that treatment can be safely reduced once you hit that goal. Talk to your doctor about whether you're a candidate for the longer interval.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open psoriasis trials

RecruitingInterventional study

Deployment o the Multidisciplinary Prospective Cohort Imminent

Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions. Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment. These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.

Lille, France
RecruitingInterventional study

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

East Windsor, New Jersey, United States